Table 3.
Patient Outcomes After Liver Transplant Evaluation in Competing Risks Analysis
| Incidence per 100 Person‐Years (95% CI) | Cumulative Incidence |
SHR (95% CI) |
Adjusted SHR (95% CI)a |
|||||
|---|---|---|---|---|---|---|---|---|
| Person‐Years | 1‐Year | 5‐Year | 10‐Year |
Gray's Test P |
||||
| Death | ||||||||
| No splenorenal shunt | 1,225 | 19.4 (17.1‐22.1) | 21.1% | 36.4% | 41.4% | 0.08 | Ref | Ref |
| Splenorenal shunt | 388 | 15.5 (12.0‐19.9) | 15.6% | 29.5% | 33.5% | 0.79 (0.60‐1.04) | 0.81 (0.60‐1.13) | |
| Liver transplantation | ||||||||
| No splenorenal shunt | 1,225 | 10.9 (9.2‐13.0) | 16.0% | 22.4% | 23.4% | 0.99 | Ref | Ref |
| Splenorenal shunt | 388 | 10.8 (8.0‐14.7) | 12.7% | 22.5% | 24.3% | 1.02 (0.73‐1.43) | 1.02 (0.68‐1.54) | |
a
Adjusted for age, sex, imaging modality, portal vein thrombosis, endoscopic varices, ascites, liver disease etiology, history of spontaneous bacterial peritonitis, history of variceal bleed, and use of diuretics.